A reduced fixed dose of Tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease

A reduced fixed dose of Tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease

Introduction. The deregulated excessive pro-inflammatory cytokine secretion has a detrimental impact on the evolution of COVID-19, aggregating tissue impairment, organ failure, and increasing the risk for death. Several studies have demonstrated the beneficial effect of Tocilizumab (TCZ) in reducing...

Full description

Bibliographic Details
Main Authors: Stela COJOCARU, Irina RUSSU, Galina BUTA, Sebastian BERSAN, Valentina POTÎNG-RAȘCOV, Natalia CULIUC, Lilia BABA
Format: Article
Language:English
Published: Asociatia de Biosiguranta si Biosecuritate 2024-10-01
Series:One Health & Risk Management
Subjects:
covid-19
cytokine storm
tocilizumab
Online Access:https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/374

Internet

https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/374

Similar Items